Answers are grounded in this paper and cite their sources.
Syndecan-2 (SDC-2) is a cell surface heparan sulfate proteoglycan whose transmembrane domain (TMD)-mediated dimerization regulates colon cancer cell behavior. In addition to functioning as a membrane receptor, SDC-2 undergoes matrix metalloproteinase-7 (MMP-7)-mediated ectodomain shedding, producing soluble fragments that promote angiogenesis and tumor progression. However, the mechanistic link between TMD-mediated dimerization and ectodomain shedding has remained unclear. Here, we show that different SDC family members exhibit distinct propensities for SDS-resistant dimer formation, which correlate with their susceptibility to MMP-7-mediated cleavage. Notably, the dimeric forms of both SDC-2 and SDC-4 were cleaved more rapidly by MMP-7, whereas dimerization-defective mutants of SDC-2 (S2GL) and SDC-4 (S4GL) displayed significantly reduced proteolytic cleavage in vitro. Conditioned media from cells expressing wild-type SDC-2 (HT29-S2W) contained elevated levels of shed SDC-2 and promoted increased migration of HT29 colon cancer cells and macrophages. In contrast, this effect was diminished in media from cells expressing the dimerization-defective S2GL mutant. Furthermore, a TMD mutant of SDC-2 identified in colon cancer patients showed impaired dimerization and decreased ectodomain shedding. Together, these findings demonstrate that TMD-mediated dimerization is required for MMP-7-dependent shedding of SDC-2 and drives tumor progression by enhancing cancer cell migration and immune cell recruitment.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: